Related coverage linked through entity extraction aliases.
Jun 09, 2026
FDA granted priority review to Sanofi's venglustat for type 3 Gaucher disease (action date Nov 25, 2026). Phase 3 LEAP2MONO data showed venglustat met both primary endpoints and three of four key secondary endpoints.
May 08, 2026
Zai Lab's Q1 2026 revenue fell 6% to $99.6 million, missing expectations, while EPS beat at -$0.05. The company highlighted Zoci intracranial response data and expects three pivotal trials by year-end 2026.
Jul 05, 2026
XBiotech Inc. (NASDAQ: XBIT) is a clinical-stage biopharmaceutical company specializing in True Human monoclonal antibodies. Pipeline candidates include Natrunix and Hutrukin. The company is held by small-cap value ETFs.
Apr 30, 2026
CRISPR therapies for alpha-1 antitrypsin deficiency advanced: BEAM-302 posted positive Phase 1/2 data, TSRA-196 gained FDA fast track/orphan status, and YOLT-202 raised AAT above the protective threshold.
May 15, 2026
The FDA's January draft guidance proposes MRD-negative complete response as an accelerated approval end point for multiple myeloma drugs. It defines MRD negativity, sets trial design requirements, and accepts comments through March 23, 2026. Expert Nicholas Richardson discusses calibration challenges and the single-trial model.
Jun 08, 2026
UKCA approval was granted for the LVOne stroke blood test, piloting with London Ambulance Service. A phase 2 trial showed LT 3001 is safe up to 24 hours post-stroke; 'leaky core' imaging links barrier disruption to worse outcomes.
Jun 27, 2026
Mexico and Finland cut clinical trial approvals to 30 days; the EU Biotech Act proposes faster timelines and harmonized rules. Finland will also establish FinTrials to boost clinical research.
Aug 04, 2026
Biocon's Yesafili, an interchangeable aflibercept biosimilar, is now available in the U.S., while Zydus Lifesciences launched Anyra in India. Both aim to treat retinal diseases such as diabetic macular edema. Biocon plans further launches in the UK and other markets, as competition intensifies.
Aug 02, 2026
Medivir AB completed an oversubscribed share issue to fund MIV-711 for Legg-Calvé-Perthes disease. MIV-711 is advancing to phase II for osteogenesis imperfecta with FDA orphan drug status. Cash runway extends to 2028 and other pipeline programs are progressing.
Aug 01, 2026
Multiple myeloma immunotherapies like bispecific antibodies and CAR-T cells show high response rates and prolonged survival, but access is hindered by the need for initial hospital stays for bispecifics. Research indicates mezigdomide can reverse T cell exhaustion to boost these therapies, while longer-term CARVYKTI data show significant survival benefits.
Aug 01, 2026
The FDA has posted recall announcements for two products: Midwest Poultry Services is recalling 1.59 million dozen eggs due to possible Salmonella contamination, and Green Lumber Holding warns that counterfeit dietary supplements contain undeclared tadalafil, which could interact dangerously with certain medications.
Aug 01, 2026
The Senate HELP Committee advanced a bill to streamline biosimilar approvals by relying on analytical tests, potentially cutting development costs and time. The FDA has issued guidance removing comparative efficacy studies and is working to speed post-exclusivity approvals. Combined with administration support and PBM reforms, these moves aim to increase biosimilar competition and reduce drug prices.
Jul 31, 2026
A Cochrane review of 17 trials finds amyloid-beta-targeted monoclonal antibodies offer negligible benefit in MCI or mild Alzheimer’s. In a phase 3 trial, the oral agent valiltramiprosate (ALZ-801) showed significant cognitive and functional improvements in the MCI subgroup, with no brain swelling risk. The company plans another phase 3 study in 2026.
Jul 31, 2026
Abivax aligned with FDA on obefazimod NDA strategy for ulcerative colitis, targeting filing by end‑2026. Phase 3 ABTECT data at ECCO 2026 showed early symptom relief and positive DSMB safety review. Leadership appointments support potential commercialization.
Jul 30, 2026
Zemcelpro (dorocubicel) has achieved NUB Status 1 in Germany, enabling hospitals to seek temporary reimbursement, while Cordex Biologics expanded access to Asia and Argentina through a distribution deal with FarmaMondo. The cell therapy holds conditional EU authorization for certain blood cancers.
Jul 30, 2026
The FDA granted RMAT designation to Allogene’s cema-cel for first-line LBCL consolidation and Cellectis’ lasme-cel for r/r B-ALL. Both allogeneic CAR-T therapies showed promising early efficacy and safety, with cema-cel also receiving Fast Track status.
Jul 29, 2026
The FDA granted Fast Track Designation to Quoin's QRX003 for Netherton Syndrome and supported NRx's NRX-100 NDA path under Fast Track for treatment-resistant depression, addressing serious unmet needs.
Jul 28, 2026
A study using FAERS and MEPS data found that oral contraceptive side effects such as acne, migraine, anxiety, and depression vary by progestin type. Drospirenone-containing pills had higher reported rates of all four, while acne was also greater with levonorgestrel and norgestimate.
Jul 29, 2026
Kintsugi, a startup developing AI to detect depression and anxiety from voice, is shutting down and open-sourcing its technology due to costly FDA regulatory hurdles. The company’s models analyzed brief speech samples and showed significantly higher depression detection rates than standard questionnaires in a health payer trial. The release aims to empower global research into voice biomarkers for mental healthcare.
Jul 27, 2026
Rising Pharma Holdings Inc. recalls four lots of 5 mg cetirizine hydrochloride allergy tablets after a pharmacy tech noticed possible cross-contamination with ranitidine, posing life-threatening risks to hypersensitive individuals.
